Lenvima (Lenvatinib) is a prescription medication used to treat specific types of cancer, including differentiated thyroid cancer (DTC) and advanced renal cell carcinoma (RCC). As a tyrosine kinase inhibitor (TKI), Lenvima works by targeting proteins that promote cancer cell growth and blood vessel formation, slowing tumor progression.
For patients with differentiated thyroid cancer, Lenvima is indicated for locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. This includes cases where the cancer has spread and is no longer responsive to radioactive iodine therapy. In kidney cancer treatment, Lenvima is used in combination with everolimus for advanced renal cell carcinoma after prior anti-angiogenic therapy has been ineffective.
Lenvima is available in oral capsule form, with dosages tailored to each condition. Typical starting doses include 24 mg daily for DTC and 18 mg daily (with everolimus) for RCC, with adjustments based on individual response and tolerance. Common side effects may include fatigue, nausea, diarrhea, high blood pressure, loss of appetite, and hand-foot syndrome. Regular monitoring by healthcare providers ensures safe and effective treatment.
Patients in the USA, UK, and Canada can purchase Lenvima from licensed pharmacies online, providing safe, secure, and timely delivery. By following your physician’s guidance and adhering to prescribed dosages, Lenvima can effectively manage tumor progression and support overall treatment plans.